Clinical Trials Browser

fosaprepitant × Breast × Clear all

NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Phase 4 Not yet recruiting

Breast Neoplasms, Vomiting

NCT01649258 2017-11-17

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Phase 1 Terminated

Breast Neoplasms, Nausea, Vomiting